AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10692000 — intervention group
Group type: COMPARATOR
Intervention: Conventional thoracic surgery
Number of subjects: 41
Study 9172724 — intervention group
Group type: EXPERIMENTAL
Intervention: Premixing propofol with lidocaine 0.05%
Number of subjects: 0
Study 9172724 — intervention group
Group type: EXPERIMENTAL
Intervention: Preinjecting lidocaine in a hand vein with a tourniquet
Number of subjects: 0
Study 1375391 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable metal endoprosthesis
Number of subjects: 35
Study 2865719 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg/kg
Number of subjects: 60
Study 2865719 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 4 mg/kg
Number of subjects: 60
Study 30868692 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping (DCM)
Number of subjects: 224
Study 30868692 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 224
Study 29481430 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and oxycodone
Number of subjects: 127
Study 29481430 — intervention group
Group type: COMPARATOR
Intervention: Midazolam and sufentanil
Number of subjects: 127
Study 27077832 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin solution between 8 and 12 hours post burn (n = 23)
Number of subjects: 46
Study 27077832 — intervention group
Group type: COMPARATOR
Intervention: Control group received 5% albumin solution 24 hours post burn (n = 23)
Number of subjects: 46
Study 23015512 — intervention group
Group type: EXPERIMENTAL
Intervention: ER-fMRI
Number of subjects: 45
Study 23015512 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression using fMRI amplitude in right posterior cingulate and insular cortex
Number of subjects: 45
Study 23015512 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian logistic regression and multilayer perceptron algorithms
Number of subjects: 45
Study 22522549 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (ETA receptor antagonist) at 400 nmol/minute for 60 minutes
Number of subjects: 57
Study 22522549 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (ETA receptor antagonist)
Number of subjects: 57
Study 22522549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 20105313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home residents with stroke (n = 257)
Number of subjects: 3239
Study 17827142 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 day antibiotic therapy
Number of subjects: 0
Study 17827142 — intervention group
Group type: COMPARATOR
Intervention: 8 day antibiotic therapy
Number of subjects: 0
Study 16210705 — intervention group
Group type: EXPERIMENTAL
Intervention: High vegetable and fruit diet (9.2 servings/d)
Number of subjects: 246
Study 16210705 — intervention group
Group type: COMPARATOR
Intervention: Low vegetable and fruit diet (3.6 servings/d)
Number of subjects: 246
Study 16210705 — intervention group
Group type: COMPARATOR
Intervention: Run-in diet (3.0 servings/d)
Number of subjects: 246
Study 16210705 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch from low to high vegetable and fruit diet
Number of subjects: 246
Study 11172215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate administered every 6 hours for 15 days (group A)
Number of subjects: 28
Study 11172215 — intervention group
Group type: COMPARATOR
Intervention: Water for injection with strawberry flavor as placebo (group B)
Number of subjects: 28
Study 9512231 — intervention group
Group type: EXPERIMENTAL
Intervention: Falloposcopic tuboplasty (FT)
Number of subjects: 50
Study 7748920 — intervention group
Group type: EXPERIMENTAL
Intervention: i.n. sCT 200 U/day
Number of subjects: 28
Study 7748920 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. sCT 100 U/day
Number of subjects: 28
Study 7748920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3173616 — intervention group
Group type: EXPERIMENTAL
Intervention: CA.RP (keto-analogs with low protein diet 0.4 g/kg/day)
Number of subjects: 15
Study 3173616 — intervention group
Group type: EXPERIMENTAL
Intervention: CA.RN (keto-analogs with normal protein diet 1 g/kg/day)
Number of subjects: 15
Study 31157963 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice daily)
Number of subjects: 154
Study 31157963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 31157963 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 154
Study 28515063 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable juices (beet, celery, and carrot) for 1 month starting at 0.5 months postpartum
Number of subjects: 97
Study 28515063 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable juices (beet, celery, and carrot) for 3 months starting at 0.5 months postpartum
Number of subjects: 97
Study 28515063 — intervention group
Group type: COMPARATOR
Intervention: Control group (water)
Number of subjects: 97
Study 28515063 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable juices (beet, celery, and carrot)
Number of subjects: 97
Study 25471002 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 0
Study 25471002 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral agents
Number of subjects: 0
Study 25471002 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS and Antiviral agents
Number of subjects: 0
Study 25471002 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study 23458906 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy combined with parenting enhancement
Number of subjects: 226
Study 23458906 — intervention group
Group type: COMPARATOR
Intervention: Equal attention-control condition
Number of subjects: 226
Study 21673005 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg on alternate days
Number of subjects: 39757
Study 21673005 — intervention group
Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 39757
Study 18685525 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltose (MAL)
Number of subjects: 9
Study 18685525 — intervention group
Group type: EXPERIMENTAL
Intervention: Trehalose (TRE)
Number of subjects: 9
Study 18685525 — intervention group
Group type: COMPARATOR
Intervention: Water (WAT)
Number of subjects: 9
Study 16492699 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 21
Study 16492699 — intervention group
Group type: COMPARATOR
Intervention: Snack (without or with acarbose)
Number of subjects: 21
Study 16492699 — intervention group
Group type: COMPARATOR
Intervention: Uncooked cornstarch
Number of subjects: 21
Study 16492699 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 21
Study 12612223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal r‐h CuZnSOD (5 mg/kg in 2 mL/kg saline) every 48 hours for up to 1 month
Number of subjects: 302
Study 12612223 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 48 hours for up to 1 month
Number of subjects: 302
Study 12612223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal r‐h CuZnSOD (5 mg/kg in 2 mL/kg saline)
Number of subjects: 302
Study 12612223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 10805052 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil/hydrochlorothiazide 8/12.5 mg once daily
Number of subjects: 353
Study 10805052 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril/hydrochlorothiazide 10/12.5 mg once daily
Number of subjects: 353
Study 8680285 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade cold blood cardioplegia (Group I, n=52)
Number of subjects: 120
Study 8680285 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antegrade/retrograde cardioplegia via coronary sinus cannulation (Group II, n=68)
Number of subjects: 120
Study 8680285 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group I and Group II)
Number of subjects: 120
Study 6441624 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen and calcium treatment
Number of subjects: 0
Study 6441624 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31754080 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed flavonoid supplementation (678 mg total, including 200 mg quercetin, 368 mg green tea catechins, 128 mg anthocyanins)
Number of subjects: 22
Study 31754080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 29098555 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cisplatin, etoposide, and irinotecan
Number of subjects: 0
Study 29098555 — intervention group
Group type: COMPARATOR
Intervention: Topotecan alone
Number of subjects: 0
Study 27136894 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based peer-support group
Number of subjects: 124
Study 27136894 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 124
Study 24308676 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine (BA) supplementation
Number of subjects: 30
Study 24308676 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 30
Study 22697628 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen membrane (CM)
Number of subjects: 72
Study 22697628 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene (e-PTFE) membrane
Number of subjects: 72
Study 22697628 — intervention group
Group type: COMPARATOR
Intervention: Control group (implants surrounded by bone, no GBR)
Number of subjects: 72
Study 22697628 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 21271025 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional bevel-up tip position (GI)
Number of subjects: 25
Study 21271025 — intervention group
Group type: COMPARATOR
Intervention: Bevel-down tip position (GII)
Number of subjects: 25
Study 17962331 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stress
Number of subjects: 17
Study 15823832 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 0
Study 15823832 — intervention group
Group type: COMPARATOR
Intervention: Randomized clinical trials
Number of subjects: 0
Study 12660500 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin 2 mg/day
Number of subjects: 31
Study 12660500 — intervention group
Group type: COMPARATOR
Intervention: Control (no rapamycin)
Number of subjects: 31
Study 10589950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (1 or 3 mg/m2/day) with full‐dose CsA
Number of subjects: 149
Study 10589950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (1, 3, or 5 mg/m2/day) with reduced‐dose CsA
Number of subjects: 149
Study 10589950 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo with full‐dose CsA)
Number of subjects: 149
Study 10589950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (3 mg/m2/day) with full‐dose CsA
Number of subjects: 149
Study 10589950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus with CsA and steroids
Number of subjects: 149
Study 10589950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus with CsA
Number of subjects: 149
Study 8929747 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 30 mg 3 times daily
Number of subjects: 20
Study 8929747 — intervention group
Group type: COMPARATOR
Intervention: Warfarin 25 mg oral dose
Number of subjects: 20
Study 1926311 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular blood donation by elderly
Number of subjects: 244
Study 6355792 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1.0 g/day)
Number of subjects: 25
Study 6355792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 6732224 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 10% acyclovir in polyethylene glycol ointment
Number of subjects: 352
Study 6732224 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol alone (control)
Number of subjects: 352
Study 30563118 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyeglasses promotion program
Number of subjects: 0
Study 30563118 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyeglasses promotion program (subgroup analysis)
Number of subjects: 0
Study 26649651 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus A9-eluting stent (BES)
Number of subjects: 1707
Study 26649651 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 1707
Study 24394383 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 50 mg/day
Number of subjects: 0
Study 24394383 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/day
Number of subjects: 0
Study 24394383 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/day
Number of subjects: 0
Study 24394383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22706937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve brace
Number of subjects: 28
Study 22706937 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid shell brace
Number of subjects: 28
Study 22706937 — intervention group
Group type: COMPARATOR
Intervention: Non-braced condition
Number of subjects: 28
Study 21235040 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (up to 10 sessions, average of 8.6 sessions per patient)
Number of subjects: 133
Study 21235040 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 133
Study 18524684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/d
Number of subjects: 750
Study 18524684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/d
Number of subjects: 750
Study 18524684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/d
Number of subjects: 750
Study 18524684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study 15845676 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative music
Number of subjects: 80
Study 15845676 — intervention group
Group type: COMPARATOR
Intervention: White noise
Number of subjects: 80
Study 15845676 — intervention group
Group type: COMPARATOR
Intervention: Operating room noise
Number of subjects: 80
Study 12588269 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin with provisional Gp IIb/IIIa inhibition (n = 2999)
Number of subjects: 6010
Study 12588269 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus planned Gp IIb/IIIa inhibition (n = 3011)
Number of subjects: 6010
Study 12588269 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 6010
Study 12588269 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus planned Gp IIb/IIIa inhibition
Number of subjects: 6010
Study 10534851 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound images transmitted at 384 kbit/s
Number of subjects: 200
Study 10534851 — intervention group
Group type: COMPARATOR
Intervention: Dynamic ultrasound images transmitted at 128 kbit/s
Number of subjects: 200
Study 9546934 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin administration via nomogram (Group I)
Number of subjects: 161
Study 9546934 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing scheme (Group II)
Number of subjects: 161
Study 9546934 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing scheme (Group III)
Number of subjects: 161
Study 1866869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg p.o.
Number of subjects: 0
Study 1866869 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 1.5 mg/kg IV
Number of subjects: 0
Study 6337697 — intervention group
Group type: COMPARATOR
Intervention: DES 1 mg orally three times daily or orchiectomy
Number of subjects: 246
Study 6337697 — intervention group
Group type: EXPERIMENTAL
Intervention: DES plus cyclophosphamide at 1 mg/m2 iv every three weeks
Number of subjects: 246
Study 6337697 — intervention group
Group type: EXPERIMENTAL
Intervention: Estracyt plus cyclophosphamide at 1 g/m2 iv every three weeks
Number of subjects: 246
Study 6337697 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (DES plus cyclophosphamide or Estracyt plus cyclophosphamide)
Number of subjects: 246
Study 6337697 — intervention group
Group type: COMPARATOR
Intervention: Hormone therapy alone
Number of subjects: 246
Study 30825673 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 wedges
Number of subjects: 12
Study 30825673 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 wedges
Number of subjects: 12
Study 30825673 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 wedges
Number of subjects: 12
Study 30825673 — intervention group
Group type: COMPARATOR
Intervention: 0, 3, and 5 wedges
Number of subjects: 12
Study 29045520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (140 mg/day)
Number of subjects: 330
Study 29045520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 29045520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (140 mg/day) in RET M918T-positive tumors
Number of subjects: 330
Study 29045520 — intervention group
Group type: COMPARATOR
Intervention: Placebo in RET M918T-positive tumors
Number of subjects: 330
Study 29045520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (140 mg/day) in RET M918T-negative tumors
Number of subjects: 330
Study 29045520 — intervention group
Group type: COMPARATOR
Intervention: Placebo in RET M918T-negative tumors
Number of subjects: 330
Study 25271811 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose losartan 50 mg/hydrochlorothiazide 12.5 mg/amlodipine 5 mg (L50/H12.5/A5)
Number of subjects: 0
Study 25271811 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg/hydrochlorothiazide 12.5 mg (L50/H12.5)
Number of subjects: 0
Study 24298783 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture with basic treatment (psychological counseling and Chinese patent medicine Rupixiao)
Number of subjects: 121
Study 24298783 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment with basic treatment only
Number of subjects: 121
Study 22292367 — intervention group
Group type: EXPERIMENTAL
Intervention: Kudiezi injection plus traditional Chinese medicine (TCM) synthesis rehabilitation project
Number of subjects: 700
Study 22292367 — intervention group
Group type: COMPARATOR
Intervention: Synthetic rehabilitation project (Control)
Number of subjects: 700
Study 19332202 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) and stenting with optimal medical therapy (1,101 patients)
Number of subjects: 2201
Study 19332202 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone (1,100 patients)
Number of subjects: 2201
Study 19332202 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI in non-LAD group
Number of subjects: 2201
Study 19332202 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy in non-LAD group
Number of subjects: 2201
Study 16972811 — intervention group
Group type: EXPERIMENTAL
Intervention: Written emotional disclosure about stressful experiences
Number of subjects: 83
Study 16972811 — intervention group
Group type: COMPARATOR
Intervention: Control writing about neutral time management
Number of subjects: 83
Study 15217075 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (n=18)
Number of subjects: 33
Study 15217075 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=7)
Number of subjects: 33
Study 15217075 — intervention group
Group type: COMPARATOR
Intervention: Time (n=8)
Number of subjects: 33
Study 11424169 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of a depression health specialist in primary care practices
Number of subjects: 0
Study 11424169 — intervention group
Group type: COMPARATOR
Intervention: Enhanced care arm (TAU with screening and assessment services)
Number of subjects: 0
Study 9470078 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume group received a rapid (10‐min) 6 ml/kg infusion of a 6% hydroxyethyl starch preparation during mechanical ventilation (MV).
Number of subjects: 18
Study 9470078 — intervention group
Group type: COMPARATOR
Intervention: Control group did not receive volume loading.
Number of subjects: 18
Study 7887106 — intervention group
Group type: EXPERIMENTAL
Intervention: HF+TEA group (high-dose fentanyl + TEA with 10 ml bupivacaine 5 mg.ml‐1 followed by 4 ml every hour)
Number of subjects: 30
Study 7887106 — intervention group
Group type: EXPERIMENTAL
Intervention: LF+TEA group (low-dose fentanyl + TEA)
Number of subjects: 30
Study 7887106 — intervention group
Group type: COMPARATOR
Intervention: HF group (high-dose fentanyl 55 micrograms.kg‐1)
Number of subjects: 30
Study 7887106 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural groups (HF+TEA and LF+TEA)
Number of subjects: 30
Study 7887106 — intervention group
Group type: COMPARATOR
Intervention: HF group
Number of subjects: 30
Study 7887106 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural group patients
Number of subjects: 30
Study 2974978 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg dose of synthetic human calcitonin administered 6-hourly by intravenous route
Number of subjects: 40
Study 2974978 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg dose of synthetic human calcitonin administered 6-hourly by intravenous route
Number of subjects: 40
Study 2974978 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental doses of calcitonin after 3 injections if blood calcium level had not been reduced by more than 0.4 mmoles/l
Number of subjects: 40
Study 2974978 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 40
Study 30590503 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic iliac perfusion (group A)
Number of subjects: 190
Study 30590503 — intervention group
Group type: COMPARATOR
Intervention: Deep hypothermic circulatory arrest (group B)
Number of subjects: 190
Study 28461129 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensible lumbar belt
Number of subjects: 57
Study 28461129 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-extensible lumbar belt
Number of subjects: 57
Study 28461129 — intervention group
Group type: COMPARATOR
Intervention: No lumbar belt
Number of subjects: 57
Study 25599346 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with voriconazole and anidulafungin
Number of subjects: 454
Study 25599346 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole monotherapy
Number of subjects: 454